Bausch + Lomb Past Earnings Performance
Past criteria checks 0/6
Bausch + Lomb's earnings have been declining at an average annual rate of -72.5%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 5.3% per year.
Key information
-72.5%
Earnings growth rate
-73.3%
EPS growth rate
| Medical Equipment Industry Growth | 4.3% |
| Revenue growth rate | 5.3% |
| Return on equity | -5.3% |
| Net Margin | -7.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bausch + Lomb makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,684 | -368 | 2,033 | 330 |
| 30 Jun 24 | 4,495 | -456 | 1,940 | 328 |
| 31 Mar 24 | 4,314 | -337 | 1,822 | 329 |
| 31 Dec 23 | 4,146 | -260 | 1,736 | 324 |
| 30 Sep 23 | 3,969 | -207 | 1,639 | 322 |
| 30 Jun 23 | 3,904 | -141 | 1,612 | 317 |
| 31 Mar 23 | 3,810 | -104 | 1,553 | 307 |
| 31 Dec 22 | 3,768 | 6 | 1,478 | 307 |
| 30 Sep 22 | 3,773 | 58 | 1,457 | 299 |
| 30 Jun 22 | 3,780 | 136 | 1,414 | 285 |
| 31 Mar 22 | 3,773 | 175 | 1,414 | 281 |
| 31 Dec 21 | 3,765 | 182 | 1,389 | 271 |
| 30 Sep 21 | 3,708 | -78 | 1,355 | 267 |
| 30 Jun 21 | 3,675 | -53 | 1,319 | 265 |
| 31 Mar 21 | 3,517 | -44 | 1,266 | 257 |
| 31 Dec 20 | 3,412 | -18 | 1,253 | 253 |
| 31 Dec 19 | 3,778 | 298 | 1,382 | 258 |
| 31 Dec 18 | 3,665 | 710 | 1,327 | 221 |
Quality Earnings: S2L is currently unprofitable.
Growing Profit Margin: S2L is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: S2L is unprofitable, and losses have increased over the past 5 years at a rate of 72.5% per year.
Accelerating Growth: Unable to compare S2L's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: S2L is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).
Return on Equity
High ROE: S2L has a negative Return on Equity (-5.31%), as it is currently unprofitable.